SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
11 Oct 2017
SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial
SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple M...
Upcoming Events
13 Sep 2017 - 16 Sep 2017, Houston, TX, USA
Society of Hematologic Oncology - 2017 Annual Meeting
26 Sep 2017 - 26 Sep 2017, Prague, Czech Republic
Translational Medicine '17
04 Oct 2017 - 05 Oct 2017, Maison du Savoir at Campus Belval, Luxembourg
4th International Systems Biomedicine Symposium: Impact of big data analytics on healthcare